Puma Biotechnology (PBYI) Payables (2011 - 2026)

Puma Biotechnology has reported Payables for 16 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 35.51% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (up 35.51% YoY), and the FY2025 full-year result was $5.1 million, down 8.22% from the prior year.
• Payables for Q1 2026 stood at $8.2 million, up from $5.1 million in the prior quarter.
• The five-year high for Payables was $14.9 million in Q3 2022, with the low at $5.1 million in Q4 2025.
• Historically, Payables has averaged $7.9 million across 5 years, with a median of $7.4 million in 2022.
• Annual changes were most pronounced in 2023 — Payables tumbled 66.09% — and 2024, when it jumped 73.19%.
• Puma Biotechnology's Payables stood at $6.4 million in 2022, then increased by 6.97% to $6.9 million in 2023, then fell by 20.03% to $5.5 million in 2024, then slipped by 8.22% to $5.1 million in 2025, then jumped by 61.51% to $8.2 million in 2026.
• The last three Payables figures came in at $8.2 million (Q1 2026), $5.1 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.